Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
, , ,
These are framed as goals patients pursue, not promises
Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
These medications, once primarily diabetes drugs to manage blood glucose levels, now stand as backbone therapies for complex cardiometabolic conditions
US$ 23.53
US$ 28.22
US$ 26.37
US$ 22.57
